drugset / Trial / NCT01992159

Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis

NCT01992159

Phase 2 Completed 252 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if treatment with romosozumab increases bone mineral density in Japanese women with postmenopausal osteoporosis.

Timeline

Start
2012-10-12
Primary completion
2014-10-09
Completion
2015-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Romosozumab Monoclonal antibody 70 mg Subcutaneous
Subject Romosozumab Monoclonal antibody 140 mg Subcutaneous
Subject Romosozumab Monoclonal antibody 210 mg Subcutaneous